Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

ClinicalTrials.gov ID: NCT00003518

Public ClinicalTrials.gov record NCT00003518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus gemcitabine in treating patients with refractory metastatic germ cell tumors that have not responded to surgery or chemotherapy.

Study identification

NCT ID
NCT00003518
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
44 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 25, 1999 (Actual)
Primary completion
Jul 2002 (Actual)
Completion
Not listed
Last update posted
Jun 22, 2023

Started 1999

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
CCOP - Colorado Cancer Research Program, Inc. Denver Colorado 80209-5031 —
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago Illinois 60611 —
Veterans Affairs Medical Center - Chicago (Lakeside) Chicago Illinois 60611 —
CCOP - Carle Cancer Center Urbana Illinois 61801 —
Indiana University Cancer Center Indianapolis Indiana 46202-5265 —
Veterans Affairs Medical Center - Indianapolis (Roudebush) Indianapolis Indiana 46202 —
CCOP - Cedar Rapids Oncology Project Cedar Rapids Iowa 52403-1206 —
CCOP - Ochsner New Orleans Louisiana 70121 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
CCOP - Kalamazoo Kalamazoo Michigan 49007-3731 —
CCOP - Metro-Minnesota Saint Louis Park Minnesota 55416 —
Hackensack University Medical Center Hackensack New Jersey 07601 —
Kimball Medical Center Lakewood New Jersey 08701 —
Morristown Memorial Hospital Morristown New Jersey 07962-1956 —
University of Rochester Cancer Center Rochester New York 14642 —
Ireland Cancer Center Cleveland Ohio 44106-5065 —
Hahnemann University Hospital Philadelphia Pennsylvania 19102-1192 —
CCOP - Marshfield Medical Research and Education Foundation Marshfield Wisconsin 54449 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2023 · Synced Nov 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00003518 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →